<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>High-dose chemotherapy with autologous SCT has become standard of care for patients with relapsed aggressive non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) </plain></SENT>
<SENT sid="1" pm="."><plain>To improve safety and efficacy of this treatment, new conditioning regimens are being developed </plain></SENT>
<SENT sid="2" pm="."><plain>We retrospectively reviewed clinical data of patients with relapsed NHL treated at our institution with i.v </plain></SENT>
<SENT sid="3" pm="."><plain>BU and CY (BU/CY) as conditioning regimen for autologous SCT between January 2000 and April 2005 </plain></SENT>
<SENT sid="4" pm="."><plain>We identified 43 patients (24 men, 19 women, median age 50) with diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=28), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=8), mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=4) and peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=3) </plain></SENT>
<SENT sid="5" pm="."><plain>Following salvage chemotherapy, there were 26 complete responses, 13 partial responses and 4 stable diseases </plain></SENT>
<SENT sid="6" pm="."><plain>Median time to neutrophil and platelet recovery was 11 and 13.5 days, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment-related toxicities included <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo> and mucositis </plain></SENT>
<SENT sid="8" pm="."><plain>The 100-day mortality was 9%: <z:hpo ids='HP_0100806'>sepsis</z:hpo> (n=1), <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (n=1) and <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">hepatic veno-occlusive disease</z:e> (n=2) </plain></SENT>
<SENT sid="9" pm="."><plain>Twenty-one patients were followed until <z:hpo ids='HP_0011420'>death</z:hpo> and twenty-one surviving patients were followed for a median of 29 months (range 0.4-76) </plain></SENT>
<SENT sid="10" pm="."><plain>Three-year estimates of event-free survival, progression-free survival and overall survival were 35, 39 and 43%, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that i.v </plain></SENT>
<SENT sid="12" pm="."><plain>BU/CY is a safe and effective conditioning regimen for autologous SCT in relapsed NHL </plain></SENT>
</text></document>